23
Participants
Start Date
January 31, 2010
Primary Completion Date
March 31, 2017
Study Completion Date
March 31, 2017
perifosine + temsirolimus
The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
Memorial Sloan-Kettering Cancer Center, New York
Collaborators (3)
University of Wisconsin, Madison
OTHER
Duke University
OTHER
NATL COMP CA NETWORK
UNKNOWN
Pfizer
INDUSTRY
AEterna Zentaris
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER